Research programme: TNF-alpha antagonists - Jerini

Drug Profile

Research programme: TNF-alpha antagonists - Jerini

Alternative Names: TNF-alpha antagonists research programme - Jerini

Latest Information Update: 29 Apr 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jerini
  • Class
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 27 Apr 2005 Discontinued - Preclinical for Inflammation in Germany (unspecified route)
  • 24 Feb 2004 Jerini's TNF-alpha antagonists research programme is available for partnering (
  • 24 Feb 2004 Preclinical trials in Inflammation in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top